Endogenous factor VIII synthesis from the intron 22-inverted F8 locus may modulate the immunogenicity of replacement therapy for hemophilia A - Wikidata - wikimedia - TriplyDB

Endogenous factor VIII synthesis from the intron 22-inverted F8 locus may modulate the immunogenicity of replacement therapy for hemophilia A

Endogenous factor VIII synthesis from the intron 22-inverted F8 locus may modulate the immunogenicity of replacement therapy for hemophilia A

http://www.wikidata.org/entity/Q30585975

about

Immunogenicity of Biotherapeutics: Causes and Association with Posttranslational Modifications FVIII inhibitors: pathogenesis and avoidance Recent Advances in Application of Pharmacogenomics for Biotherapeutics Murine coagulation factor VIII is synthesized in endothelial cells.Advancing Public Health Using Regulatory Science to Enhance Development and Regulation of Medical Products: Food and Drug Administration Research at the Center for Biologics Evaluation and Research The intron-22-inverted F8 locus permits factor VIII synthesis: explanation for low inhibitor risk and a role for pharmacogenomics Small ncRNA Expression-Profiling of Blood from Hemophilia A Patients Identifies miR-1246 as a Potential Regulator of Factor 8 Gene Game, set, match for factor VIII mismatch?In situ genetic correction of F8 intron 22 inversion in hemophilia A patient-specific iPSCs Characterization of a genetically engineered mouse model of hemophilia A with complete deletion of the F8 gene.New predictive approaches for ITI treatment.Genetic risk factors for inhibitors in haemophilia A.Engineering less immunogenic and antigenic FVIII proteins.Canine models of inherited bleeding disorders in the development of coagulation assays, novel protein replacement and gene therapies.Gene therapy for immune tolerance induction in hemophilia with inhibitors.Genetic determinants of immunogenicity to factor IX during the treatment of haemophilia B.T cells from hemophilia A subjects recognize the same HLA-restricted FVIII epitope with a narrow TCR repertoire.IDO1 suppresses inhibitor development in hemophilia A treated with factor VIII.Managing haemophilia for life: 4th Haemophilia Global Summit.Alternative therapies for the management of inhibitors.Rapid identification of the intron 22 inversion in haemophilia A.

P2860

Q26738810-0162F6B3-F093-4E8A-A43E-82FC6E10020F Q27027224-1524BADA-5A24-422F-BA09-023CF48DD9BD Q29247996-F692223C-A6DA-4EFA-850F-226F004D6F47 Q33749623-38EB9613-D178-44AB-B3E8-B899FE76FFE8 Q33785803-166FBB26-AEC2-41C4-9DF3-F5C499F49D63 Q34876672-F5A18F99-8894-49B6-8F00-5A685582E7C3 Q35692013-220D1085-A27B-4AB4-9D1F-C093DF851288 Q36015787-D7129911-CBB2-4A00-85A3-FCE14C473219 Q36442862-7C70AFAE-7D6C-4A88-9A4C-412E9D899278 Q36586264-777A04B4-078B-4E90-AF39-19C16DEB8BC1 Q38224297-D96D541E-AFBA-4F76-B692-7546A085AAAA Q38308196-92280564-DADB-471B-926B-0A8BC6649264 Q38632876-488C42DA-D65A-40DA-9077-8E753E73702D Q38754256-AE8A4487-A3BC-4D63-AB79-CF29F7584206 Q38803022-D4804FBD-D8FE-4F1D-9AA3-D437A35825A7 Q41732261-A5589607-AF05-4DD7-8180-3FC08F9E10A6 Q42381250-6FFCB6CA-A242-4CD8-AB6D-6E952FB9CC17 Q43218590-5FC8130B-746B-4DBD-806A-8F3A9C3798DE Q44122887-A6E58224-1775-427F-917F-BAB389071588 Q45856195-0B759729-3C2C-47D9-8AEF-6326B4D21BF1 Q45862677-F4570027-FF3A-420A-ABC9-2A59F1606672

P2860

Endogenous factor VIII synthesis from the intron 22-inverted F8 locus may modulate the immunogenicity of replacement therapy for hemophilia A

http://www.wikidata.org/entity/Q30585975

description

2013 nî lūn-bûn

@nan

2013 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Endogenous factor VIII synthes ...... ement therapy for hemophilia A

@ast

Endogenous factor VIII synthes ...... ement therapy for hemophilia A

@en

type

label

Endogenous factor VIII synthes ...... ement therapy for hemophilia A

@ast

Endogenous factor VIII synthes ...... ement therapy for hemophilia A

@en

prefLabel

Endogenous factor VIII synthes ...... ement therapy for hemophilia A

@ast

Endogenous factor VIII synthes ...... ement therapy for hemophilia A

@en

P1433

Q30585975-6B5CA82E-469A-4429-BBE2-D12704105AB1

P1476

Q30585975-036891BF-7BAB-458C-9A6A-D59EC17EEE76

P2093

Q30585975-0710A602-7DF0-4FBD-99BB-D9C967E6397B

Q30585975-0C52B1EF-FE2C-4866-A795-D93F81F6C638

Q30585975-112CE9EE-D0A9-45B3-B40E-CAD57AAFBC49

Q30585975-157E5D88-9506-44D7-98F3-C5163B726F0D

Q30585975-197EE41E-FF2A-4D56-BFEE-33613509F96E

Q30585975-27A3CADE-70D1-4FBD-9F3D-2419F9CA834A

Q30585975-3C8FACE7-E782-4CE5-92E7-77F3ACA87F9A

Q30585975-6126E4D2-04B7-4E8D-A8F1-410B604240DE

Q30585975-63A9860F-EB18-47F3-92B0-53C3628047F4

Q30585975-BE2866F7-0840-4BBA-9060-458B85110534

P2860

Q30585975-04330BF5-7570-4169-AD8E-6491D600862C

Q30585975-1A97CC1D-9E32-4373-85A2-3B1AAC9F4F3C

Q30585975-1EC1589A-9E8A-45D8-A21F-5E714E666EB1

Q30585975-2D921E37-8D5C-4601-84FD-9BED91A4AC88

Q30585975-38E758A9-A0F0-4C06-AC97-661121643DA8

Q30585975-632A73FE-CF2A-460F-9E16-B3CEB1D29634

Q30585975-6EB1EB74-7B75-428C-B15B-1BB74B146EC8

Q30585975-765AC693-4E32-42E6-827E-0715DF4CD209

Q30585975-8A8C06DF-A5D6-4802-85CC-4ED28B99DEC8

Q30585975-8E83184A-BA55-4CB6-B581-DD3C0DBAE713

P2888

Q30585975-9CF30CCB-0F4B-4839-B271-5EF045929F5C

P304

Q30585975-E1BCFF39-C59C-40EF-B462-FFAC677200B3

P31

Q30585975-37FD76BA-333A-42AC-B759-FF58D87C66FF

P356

Q30585975-2DF31184-7BD4-405D-A980-581643A881C5

P407

Q30585975-F0C94039-A310-440F-9E1C-B0D51F7C8235

P433

Q30585975-B8AD89D1-0E55-47FC-852B-9BFA9980A850

P478

Q30585975-88C3FF0C-4A8D-468F-9287-EF49D67C567B

P50

Q30585975-559178B9-59B0-4A1F-BA1B-94C3449CA736

Q30585975-A5A49E73-C969-4EB8-86ED-E5B5BBE27372

Q30585975-AB08F5AE-FFFA-41FE-BC19-0B779ED87E7A

Q30585975-C9D2B2E9-359E-4226-8F13-3AF2AF7C0B68

Q30585975-F19717B6-41DD-4FC1-8FFB-65B94F6730DA

Q30585975-FCB30A55-E66B-42B5-AA2C-94C7EEDCCBE0

P577

Q30585975-FF36FFD5-F11F-46A6-AAE6-58BDB9A4EF05

P5875

Q30585975-C16C4129-3010-4F8B-8D1A-CA8920A8D343

P698

Q30585975-EC2AE70E-4A88-483F-A135-030D771FEE4B

P921

Q30585975-34BB1577-72CE-4F07-B325-E3E8ED170478

Q30585975-6ECA5841-FDBE-435B-8692-6EE63DD74AF9

Q30585975-8C74E279-3FA9-4EF2-A112-3F834572F9FE

P932

Q30585975-6F6873DB-5A23-4A95-9DED-669882C665A6

P356

P1433

Nature Medicine

P1476

Endogenous factor VIII synthes ...... ement therapy for hemophilia A

@en

P2093

David Lillicrap

http://www.w3.org/2001/XMLSchema#string

Glenn F Pierce

http://www.w3.org/2001/XMLSchema#string

Gouri Shankar Pandey

http://www.w3.org/2001/XMLSchema#string

Kevin R Viel

http://www.w3.org/2001/XMLSchema#string

Lisa M Miller-Jenkins

http://www.w3.org/2001/XMLSchema#string

Natalia Rydz

http://www.w3.org/2001/XMLSchema#string

PATH (Personalized Alternative Therapies for Hemophilia) Study Investigators

http://www.w3.org/2001/XMLSchema#string

Susan Garfield

http://www.w3.org/2001/XMLSchema#string

Tom E Howard

http://www.w3.org/2001/XMLSchema#string

Vijaya Simhadri

http://www.w3.org/2001/XMLSchema#string

P2860

The genetic structure and history of Africans and African Americans

F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis

Polymorphisms in the F8 gene and MHC-II variants as risk factors for the development of inhibitory anti-factor VIII antibodies during the treatment of hemophilia a: a computational assessment

Worldwide human relationships inferred from genome-wide patterns of variation

In-gel digestion for mass spectrometric characterization of proteins and proteomes

Quantitative predictions of peptide binding to any HLA-DR molecule of known sequence: NetMHCIIpan.

The life cycle of coagulation factor VIII in view of its structure and function.

The epidemiology of inhibitors in haemophilia A: a systematic review.

F8 haplotype and inhibitor risk: results from the Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort.

Inhibitors of factor VIII in black patients with hemophilia

P2888

P304

1318-1324

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NM.3270

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

19

http://www.w3.org/2001/XMLSchema#string

P50

Teresa M. Przytycka

Chava Kimchi-Sarfaty

Joanne E Curran

P577

2013-09-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

262044779

http://www.w3.org/2001/XMLSchema#string

P698

24037092

http://www.w3.org/2001/XMLSchema#string

P921

Coagulation factor VIII

P932

4123441

http://www.w3.org/2001/XMLSchema#string